US5173414A
(en)
*
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
US6261834B1
(en)
|
1991-11-08 |
2001-07-17 |
Research Corporation Technologies, Inc. |
Vector for gene therapy
|
US5252479A
(en)
*
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
US6268213B1
(en)
|
1992-06-03 |
2001-07-31 |
Richard Jude Samulski |
Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
|
US6340674B1
(en)
|
1993-03-26 |
2002-01-22 |
Thomas Jefferson University |
Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
|
US6686200B1
(en)
|
1993-08-31 |
2004-02-03 |
Uab Research Foundation |
Methods and compositions for the large scale production of recombinant adeno-associated virus
|
US6652850B1
(en)
|
1993-09-13 |
2003-11-25 |
Aventis Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
AU688428B2
(en)
*
|
1993-11-09 |
1998-03-12 |
Johns Hopkins University, The |
Generation of high titers of recombinant AAV vectors
|
PT728214E
(pt)
*
|
1993-11-09 |
2004-11-30 |
Ohio Med College |
Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
|
FR2716682B1
(fr)
*
|
1994-01-28 |
1996-04-26 |
Centre Nat Rech Scient |
Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
|
FR2716893B1
(fr)
*
|
1994-03-03 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, leur préparation et leur utilisation thérapeutique.
|
IL113052A0
(en)
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
CA2187626C
(en)
*
|
1994-04-13 |
2009-11-03 |
Michael G. Kaplitt |
Aav-mediated delivery of dna to cells of the nervous system
|
US6013517A
(en)
*
|
1994-05-09 |
2000-01-11 |
Chiron Corporation |
Crossless retroviral vectors
|
DE69535669T2
(de)
|
1994-05-09 |
2008-12-04 |
Oxford Biomedica (Uk) Ltd. |
Retrovirale vektoren mit verminderter rekombinationsrate
|
US6814962B1
(en)
*
|
1994-06-02 |
2004-11-09 |
Aventis Pharma S.A. |
Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
|
US6204059B1
(en)
*
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
US5856152A
(en)
*
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
US5872005A
(en)
*
|
1994-11-03 |
1999-02-16 |
Cell Genesys Inc. |
Packaging cell lines for adeno-associated viral vectors
|
US5714170A
(en)
|
1994-11-16 |
1998-02-03 |
Thomas Jefferson University |
Method of inducing resistance to tumor growth
|
US6342390B1
(en)
*
|
1994-11-23 |
2002-01-29 |
The United States Of America As Represented By The Secretary Of Health And Human Services |
Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
|
US6924128B2
(en)
*
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
WO1996017947A1
(en)
*
|
1994-12-06 |
1996-06-13 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant aav vectors
|
US5843742A
(en)
*
|
1994-12-16 |
1998-12-01 |
Avigen Incorporated |
Adeno-associated derived vector systems for gene delivery and integration into target cells
|
US5780296A
(en)
*
|
1995-01-17 |
1998-07-14 |
Thomas Jefferson University |
Compositions and methods to promote homologous recombination in eukaryotic cells and organisms
|
FR2732357B1
(fr)
*
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
US7745416B2
(en)
*
|
1995-04-11 |
2010-06-29 |
The Regents Of The University Of California |
Method for in vivo regulation of cardiac muscle contractility
|
US5830725A
(en)
*
|
1995-04-28 |
1998-11-03 |
The Board Of Trustees For The Leland Stanford Junior University |
Rapid, stable high-titre production of recombing retrovirus
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
WO1996039036A1
(en)
*
|
1995-06-05 |
1996-12-12 |
The University Of Alabama At Birmingham Research Foundation |
Composition and methods for creating syngeneic recombinant virus-producing cells
|
US6093570A
(en)
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
JP4108746B2
(ja)
*
|
1995-06-07 |
2008-06-25 |
ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
ヘルパーウイルスを含まないaav産生
|
US6040183A
(en)
*
|
1995-06-07 |
2000-03-21 |
University Of North Carloina At Chapel Hill |
Helper virus-free AAV production
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
US6110456A
(en)
*
|
1995-06-07 |
2000-08-29 |
Yale University |
Oral delivery or adeno-associated viral vectors
|
FR2737501B1
(fr)
*
|
1995-07-31 |
1997-10-24 |
Transgene Sa |
Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
|
US6001650A
(en)
*
|
1995-08-03 |
1999-12-14 |
Avigen, Inc. |
High-efficiency wild-type-free AAV helper functions
|
US5622856A
(en)
*
|
1995-08-03 |
1997-04-22 |
Avigen |
High efficiency helper system for AAV vector production
|
US6027931A
(en)
|
1995-08-03 |
2000-02-22 |
Avigen, Inc. |
High-efficiency AA V helper functions
|
US5801030A
(en)
*
|
1995-09-01 |
1998-09-01 |
Genvec, Inc. |
Methods and vectors for site-specific recombination
|
WO1997016539A1
(fr)
*
|
1995-11-01 |
1997-05-09 |
Dnavec Research Inc. |
Virus sendai recombinant
|
US6086913A
(en)
*
|
1995-11-01 |
2000-07-11 |
University Of British Columbia |
Liposomal delivery of AAV vectors
|
US6004797A
(en)
*
|
1995-11-09 |
1999-12-21 |
Avigen, Inc. |
Adenovirus helper-free recombinant AAV Virion production
|
US6084085A
(en)
*
|
1995-11-14 |
2000-07-04 |
Thomas Jefferson University |
Inducing resistance to tumor growth with soluble IGF-1 receptor
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
US5874304A
(en)
*
|
1996-01-18 |
1999-02-23 |
University Of Florida Research Foundation, Inc. |
Humanized green fluorescent protein genes and methods
|
US5858351A
(en)
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
GB9614699D0
(en)
*
|
1996-07-12 |
1996-09-04 |
John P Robarts Research Inst T |
Hybrid herpes virus-based vector for gene delivery and expression
|
JP2000516472A
(ja)
*
|
1996-08-16 |
2000-12-12 |
メディカル リサーチ カウンシル |
組織特異的遺伝子発現を与える自己複製型エピソーム性発現ベクター
|
US20020037867A1
(en)
*
|
1999-02-26 |
2002-03-28 |
James M. Wilson |
Method for recombinant adeno-associated virus-directed gene therapy
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
JP2001500376A
(ja)
*
|
1996-09-06 |
2001-01-16 |
カイロン コーポレイション |
組換えaavベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
US6541258B2
(en)
|
1996-12-18 |
2003-04-01 |
Targeted Genetics Corporation |
AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
AU6962698A
(en)
|
1997-04-11 |
1998-11-11 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Transgenomic viruses and the use thereof
|
DE69840439D1
(de)
|
1997-04-24 |
2009-02-26 |
Univ Washington |
Zielgerichtete genveraenderung mit parvoviralen vektoren
|
CN1177934C
(zh)
|
1997-04-28 |
2004-12-01 |
阿文蒂斯药物股份有限公司 |
腺病毒介导的肿瘤内投送血管生成拮抗剂用于肿瘤的治疗
|
US6541036B1
(en)
|
1997-05-29 |
2003-04-01 |
Thomas Jefferson University |
Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
|
US6710036B2
(en)
|
1997-07-25 |
2004-03-23 |
Avigen, Inc. |
Induction of immune response to antigens expressed by recombinant adeno-associated virus
|
US20040161409A1
(en)
*
|
1997-07-25 |
2004-08-19 |
Kurtzman Gary J. |
Induction of immune response to antigens expressed by recombinant adeno-associated virus
|
US6221646B1
(en)
*
|
1997-07-31 |
2001-04-24 |
Chiron Corporation |
Materials and methods for simplified AAV production
|
US6037177A
(en)
*
|
1997-08-08 |
2000-03-14 |
Cell Genesys, Inc. |
Method for increasing the efficiency of recombinant AAV production
|
US6706693B1
(en)
|
1997-08-13 |
2004-03-16 |
The Uab Research Foundation |
Vaccination by topical application of genetic vectors
|
US6716823B1
(en)
|
1997-08-13 |
2004-04-06 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom, and uses thereof
|
US20030125278A1
(en)
*
|
1997-08-13 |
2003-07-03 |
Tang De-Chu C. |
Immunization of animals by topical applications of a salmonella-based vector
|
US20030045492A1
(en)
*
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
US6348450B1
(en)
*
|
1997-08-13 |
2002-02-19 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom and uses thereof
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6995006B2
(en)
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
EP1009808B1
(de)
|
1997-09-05 |
2012-12-05 |
Genzyme Corporation |
Methoden zur herstellung von helpervirusfreien präparationen von rekombinenten aav-vektoren mit hohem titer
|
GB9721909D0
(en)
*
|
1997-10-17 |
1997-12-17 |
Cantab Pharma Res |
Gene delivery vectors and their uses
|
WO1999020779A1
(en)
*
|
1997-10-21 |
1999-04-29 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus (aav) packaging cassettes for the production of recombinant aav vectors
|
US6642051B1
(en)
*
|
1997-10-21 |
2003-11-04 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
|
ATE232905T1
(de)
*
|
1997-11-05 |
2003-03-15 |
Gsf Forschungszentrum Umwelt |
Verfahren zur helfervirusfreien verpackung einer genvektor-dna
|
BR9813930A
(pt)
|
1997-11-06 |
2006-12-19 |
Chiron Spa |
antìgeno neisserial
|
ATE302267T1
(de)
|
1998-01-08 |
2005-09-15 |
Aventis Pharma Inc |
Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
|
EP1047784B2
(de)
|
1998-01-14 |
2015-03-18 |
Novartis Vaccines and Diagnostics S.r.l. |
Antigene aus neisseria meningitidis
|
DE69933856D1
(de)
|
1998-02-13 |
2006-12-14 |
Koester Hubert |
Verwendung von ribozymen zur bestimmung der funktion von genen
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
EP1982990A1
(de)
|
1998-03-19 |
2008-10-22 |
Human Genome Sciences, Inc. |
Zytokinrezeptor wie eine gemeinsame Gammakette
|
JP2002506652A
(ja)
*
|
1998-03-20 |
2002-03-05 |
トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパーを含まない製造のための組成物及び方法
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
NZ532665A
(en)
|
1998-05-01 |
2005-11-25 |
Inst Genomic Research |
Neisseria meningitidis antigens and compositions
|
ATE309352T1
(de)
*
|
1998-05-06 |
2005-11-15 |
Vlaams Interuniv Inst Biotech |
Inhibitoren der nf-kb aktivierung
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US6436392B1
(en)
*
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
GB9811172D0
(en)
*
|
1998-05-22 |
1998-07-22 |
Royal Free Hosp School Med |
Virus production
|
DE69929600T2
(de)
|
1998-05-27 |
2006-09-07 |
Avigen Inc., Alameda |
Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
|
EP1080218A1
(de)
*
|
1998-05-27 |
2001-03-07 |
University of Florida |
Methode zur darstellung von rekombinanten adeno-assoziierten virus zusammensetzungen mit hilfe von iodixanol gradienten
|
DE19833476B4
(de)
*
|
1998-07-24 |
2005-08-25 |
Huss, Ralf, Dr. |
Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie
|
WO2000012740A2
(en)
|
1998-08-28 |
2000-03-09 |
Duke University |
ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES
|
EP2942393A1
(de)
|
1998-09-04 |
2015-11-11 |
Genzyme Corporation |
Verfahren zur erzeugung helferfreier präparate mit hohem titer aus freigesetzten rekombinanten aav-vektoren
|
US6783972B1
(en)
|
1998-09-22 |
2004-08-31 |
University Of Florida Research Foundation |
Methods for large-scale production of recombinant AAV vectors
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
WO2000022152A1
(en)
*
|
1998-10-13 |
2000-04-20 |
Avigen, Inc. |
Compositions and methods for producing recombinant adeno-associated virus
|
US6200560B1
(en)
*
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
US7129043B1
(en)
*
|
1998-10-22 |
2006-10-31 |
Duke University |
Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
|
US6759237B1
(en)
*
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
AU780231B2
(en)
|
1998-11-10 |
2005-03-10 |
University Of North Carolina At Chapel Hill, The |
Virus vectors and methods of making and administering the same
|
US6303362B1
(en)
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
US6441156B1
(en)
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
CA2360347C
(en)
|
1998-12-31 |
2013-05-07 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US6387368B1
(en)
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
EP1153037A1
(de)
|
1999-02-09 |
2001-11-14 |
Lexicon Genetics Incorporated |
Menschliche entkopplende-proteine und polynukleotiden die dafür kodieren
|
DE19905501B4
(de)
|
1999-02-10 |
2005-05-19 |
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie |
Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
|
US20040043488A1
(en)
*
|
1999-02-17 |
2004-03-04 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Adeno-associated viral gene-transfer vector system
|
US6258595B1
(en)
*
|
1999-03-18 |
2001-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
US6893865B1
(en)
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
NZ571167A
(en)
|
1999-04-30 |
2010-05-28 |
Novartis Vaccines & Diagnostic |
Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
|
US20040009936A1
(en)
*
|
1999-05-03 |
2004-01-15 |
Tang De-Chu C. |
Vaccine and drug delivery by topical application of vectors and vector extracts
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
EP1939300A1
(de)
|
1999-05-28 |
2008-07-02 |
Targeted Genetics Corporation |
Verfahren und Zusammensetzung zur Senkung des Spiegels des Tumornekrosefaktors (TNF) bei TNF-assoziierten Leiden
|
DK1180159T3
(da)
*
|
1999-05-28 |
2008-11-17 |
Targeted Genetics Corp |
Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
|
US7122335B1
(en)
|
1999-06-08 |
2006-10-17 |
University Of Iowa Research Foundation |
Compounds and methods to enhance rAAV transduction
|
WO2000075365A2
(en)
*
|
1999-06-08 |
2000-12-14 |
University Of Iowa Research Foundation |
Compounds and methods to enhance raav transduction
|
WO2001000665A2
(en)
*
|
1999-06-28 |
2001-01-04 |
Oklahoma Medical Research Foundation |
Inhibitors of memapsin 2 and use thereof
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
ES2478635T3
(es)
*
|
1999-08-09 |
2014-07-22 |
Targeted Genetics Corporation |
Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios
|
EP1916258B1
(de)
|
1999-08-09 |
2014-04-23 |
Targeted Genetics Corporation |
Erweiterte Expression einer einstämmigen, heterologen Nukleotidsequenz von rekombinanten viralen Vektoren durch Modellierung der Sequenz mit stammübergreifenden Basispaaren
|
US6410236B1
(en)
|
1999-09-01 |
2002-06-25 |
The Regents Of The University Of Michigan |
Correcting diastolic dysfunction in heart failure
|
US7115391B1
(en)
*
|
1999-10-01 |
2006-10-03 |
Genovo, Inc. |
Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
|
AU7841400A
(en)
*
|
1999-10-01 |
2001-05-10 |
Genovo, Incorporated |
Production of recombinant aav using adenovirus comprising aav rep/cap genes
|
AU7739000A
(en)
|
1999-10-01 |
2001-05-10 |
University Of Florida |
Temperature-sensitive regulation of viral vector production
|
US7241447B1
(en)
*
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
AU784420B2
(en)
*
|
1999-10-07 |
2006-03-30 |
University Of Iowa Research Foundation, The |
Adeno-associated viruses and uses thereof
|
WO2001025465A1
(en)
*
|
1999-10-07 |
2001-04-12 |
University Of Iowa Research Foundation |
Adeno-associated viruses and uses thereof
|
CA2387479A1
(en)
|
1999-10-11 |
2001-04-19 |
Lexicon Genetics Incorporated |
Human ldl receptor family proteins and polynucleotides encoding the same
|
GB9924981D0
(en)
*
|
1999-10-21 |
1999-12-22 |
Univ Manchester |
Gene therapy
|
CA2426669A1
(en)
*
|
1999-10-22 |
2001-05-03 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
.alpha.1-3 galactosyltransferase gene and promoter
|
EP2975127A1
(de)
|
1999-10-29 |
2016-01-20 |
GlaxoSmithKline Biologicals SA |
Neisseria antigenpeptide
|
AUPQ425699A0
(en)
|
1999-11-25 |
1999-12-23 |
University Of Newcastle Research Associates Limited, The |
A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
|
WO2001040798A2
(en)
|
1999-12-06 |
2001-06-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
EP2275129A3
(de)
|
2000-01-17 |
2013-11-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
|
WO2001059450A2
(en)
|
2000-02-08 |
2001-08-16 |
Sangamo Biosciences, Inc. |
Cells expressing zinc finger protein for drug discovery
|
IL151097A0
(en)
|
2000-02-23 |
2003-04-10 |
Smithkline Beecham Biolog |
Tumour-specific animal proteins
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
EP1276849A4
(de)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
Albumin fusionsproteine
|
DE60139394D1
(de)
*
|
2000-04-28 |
2009-09-10 |
Asklepios Biopharmaceutical In |
Für das dystrophin-minigen kodierende dna-sequenzen und verfahren zu deren verwendung
|
US6790667B1
(en)
|
2000-05-30 |
2004-09-14 |
Lexicon Genetics Incorporated |
Human mitochondrial proteins and polynucleotides encoding the same
|
AU7541101A
(en)
*
|
2000-06-09 |
2001-12-24 |
Bristol Myers Squibb Co |
Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
|
JP2004513615A
(ja)
|
2000-06-28 |
2004-05-13 |
コリクサ コーポレイション |
肺癌の治療および診断のための組成物および方法
|
AU2001273174B2
(en)
|
2000-07-03 |
2006-05-18 |
Bristol-Myers Squibb Company |
Methods for treating rheumatic diseases using a soluble CTLA4 molecule
|
JP4762478B2
(ja)
*
|
2000-07-03 |
2011-08-31 |
キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー |
発現ベクター
|
US20030224415A1
(en)
*
|
2001-06-29 |
2003-12-04 |
Gala Design, Inc. |
Selection free growth of host cells containing multiple integrating vectors
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
US6852510B2
(en)
*
|
2000-07-03 |
2005-02-08 |
Gala Design Inc |
Host cells containing multiple integrating vectors
|
US7223406B2
(en)
*
|
2000-07-21 |
2007-05-29 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
WO2002007757A2
(en)
*
|
2000-07-21 |
2002-01-31 |
Lue Tom F |
Prevention and treatment of sexual arousal disorders
|
US6916635B2
(en)
*
|
2000-10-02 |
2005-07-12 |
The Research Foundation Of State University Of New York |
Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
|
SG165981A1
(en)
|
2000-10-27 |
2010-11-29 |
Chiron Srl |
Nucleic acids and proteins from streptococcus groups a & b
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
DE60144198D1
(de)
|
2000-12-28 |
2011-04-21 |
Wyeth Llc |
Rekombinantes schutzprotein aus streptococcus pneumoniae
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
JP2005502591A
(ja)
|
2001-01-12 |
2005-01-27 |
カイロン コーポレイション |
核酸粘膜免疫
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
US20020182595A1
(en)
*
|
2001-04-27 |
2002-12-05 |
Weitzman Matthew D. |
Method of identifying cellular regulators of adeno-associated virus (AAV)
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US6946126B2
(en)
*
|
2001-06-04 |
2005-09-20 |
Duke University |
Replicating adenovirus vectors
|
JP4252446B2
(ja)
*
|
2001-06-22 |
2009-04-08 |
フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) |
Abinにより媒介される肝炎防護
|
JP2005500835A
(ja)
*
|
2001-06-29 |
2005-01-13 |
ノバルティス アクチエンゲゼルシャフト |
Pervスクリーニング法およびその使用
|
US20030198621A1
(en)
|
2001-07-05 |
2003-10-23 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
|
JP5033303B2
(ja)
|
2001-07-05 |
2012-09-26 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
|
US8241622B2
(en)
*
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
WO2003006616A2
(en)
*
|
2001-07-13 |
2003-01-23 |
University Of Iowa Research Foundation |
Pseudotyped adeno-associated viruses and uses thereof
|
DE10137283A1
(de)
*
|
2001-08-01 |
2003-02-27 |
Deutsches Krebsforsch |
AAV-Vektor-Verpackungsplasmide zur Helfervirus-freien Herstellung pseudotypisierter AAV-Partikel über Einzeltransfektion
|
EP1427816A4
(de)
|
2001-09-18 |
2004-12-01 |
Clontech Lab Inc |
Auf stellenspezifischer rekombinase beruhendes verfahren zur herstellung von adenovirusvektoren
|
CA2461290C
(en)
|
2001-09-24 |
2014-11-25 |
Sangamo Biosciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
CA2464887A1
(en)
*
|
2001-10-30 |
2003-05-08 |
Biogen, Inc. |
Methods and compositions for treating parkinson's disease
|
CA2467959C
(en)
*
|
2001-11-09 |
2009-03-10 |
Robert M. Kotin |
Production of adeno-associated virus in insect cells
|
US6723551B2
(en)
|
2001-11-09 |
2004-04-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
ES2258601T3
(es)
*
|
2001-11-13 |
2006-09-01 |
The Trustees Of The University Of Pennsylvania |
Un metodo para la identificacion de las secuencias desconocidas del virus adeno-asociado (vaa) y un kit para el metodo.
|
US7544669B2
(en)
|
2001-11-21 |
2009-06-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Polynucleotide therapy
|
EP2335723A1
(de)
|
2001-12-12 |
2011-06-22 |
Novartis Vaccines and Diagnostics S.r.l. |
Immunisierung gegen Chlamydia trachomatis
|
CA2476755C
(en)
|
2001-12-17 |
2014-08-26 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
EP2277889B1
(de)
|
2001-12-21 |
2014-07-09 |
Human Genome Sciences, Inc. |
Fusionsproteine von Albumin und Interferon beta
|
CA2472927A1
(en)
*
|
2002-01-10 |
2003-07-17 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
A novel splice variant of myd88 and uses thereof
|
CA2369985A1
(en)
*
|
2002-01-18 |
2003-07-18 |
Duke University |
Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
|
AU2003202297C1
(en)
|
2002-01-25 |
2006-05-18 |
G2 Therapies Ltd |
Anti-C5aR antibodies and uses thereof
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
AU2003267949A1
(en)
*
|
2002-03-15 |
2003-12-31 |
U.S. Government As Represented By The Department Of Veterans Affairs |
Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
|
US20040038304A1
(en)
*
|
2002-03-28 |
2004-02-26 |
Gala Design, Inc. |
Antibody libraries
|
US7384738B2
(en)
*
|
2002-03-28 |
2008-06-10 |
Bremel Robert D |
Retrovirus-based genomic screening
|
WO2003086451A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Centocor, Inc. |
Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
|
WO2004050680A2
(en)
*
|
2002-05-08 |
2004-06-17 |
Intronn, Inc. |
Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
|
US20030219696A1
(en)
*
|
2002-05-23 |
2003-11-27 |
Moreland Gerald W. |
Method and apparatus for preventing backflow in dental saliva evacuators
|
WO2003100008A2
(en)
|
2002-05-24 |
2003-12-04 |
Schering Corporation |
Neutralizing human anti-igfr antibody
|
EP1534819B1
(de)
*
|
2002-08-21 |
2009-12-09 |
Revivicor, Inc. |
Schweine ohne jegliche expression funktioneller alpha-1,3-galactosyltransferase
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US20050260601A1
(en)
*
|
2002-09-09 |
2005-11-24 |
Whitt Michael A |
Recombinant mutants of rhabdovirus and methods of use thereof
|
US20040052161A1
(en)
*
|
2002-09-17 |
2004-03-18 |
Steven Liao |
Mechanical clock having wireless manipulation and adjustment function
|
ATE465753T1
(de)
|
2002-10-21 |
2010-05-15 |
Eisai Inc |
Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
|
ATE471387T1
(de)
*
|
2002-10-23 |
2010-07-15 |
Virxsys Corp |
Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
|
DK1569696T3
(da)
|
2002-11-21 |
2010-11-15 |
Bayhill Therapeutics Inc |
Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
|
AU2002953436A0
(en)
*
|
2002-12-18 |
2003-01-09 |
The University Of Newcastle Research Associates Limited |
A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
|
EP1576004A2
(de)
*
|
2002-12-23 |
2005-09-21 |
VIB vzw |
Ein trypanosomenprotein und dessen verwendung zur beeinflussung der immunantwort
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
RU2389732C2
(ru)
|
2003-01-06 |
2010-05-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
EP1585815A4
(de)
*
|
2003-01-21 |
2006-02-22 |
Bristol Myers Squibb Co |
Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
|
ATE521701T1
(de)
|
2003-01-22 |
2011-09-15 |
Univ Duke |
Verbesserte konstrukte zur expression lysosomaler polypeptide
|
EP1608763A2
(de)
*
|
2003-03-31 |
2005-12-28 |
University Of Iowa Research Foundation |
Verbindungen und verfahren zur verbesserung der raav-transduktion
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
CA2525825A1
(en)
|
2003-05-15 |
2005-01-27 |
Chiron Corporation |
Hiv polynucleotides and polypeptides derived from botswana mj4
|
EP2277996B1
(de)
|
2003-05-21 |
2014-09-03 |
Genzyme Corporation |
Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
|
US20050036988A1
(en)
*
|
2003-05-28 |
2005-02-17 |
Ruian Xu |
Compositions and methods for preventing and treating liver cirrhosis
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
CA2534296C
(en)
|
2003-08-08 |
2013-03-26 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
ATE518960T1
(de)
|
2003-09-19 |
2011-08-15 |
Sangamo Biosciences Inc |
Gentechnisch hergestellte zinkfingerproteine zur regulation der genexpression
|
WO2005047469A2
(en)
*
|
2003-11-05 |
2005-05-26 |
University Of Pittsburgh |
PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
|
US20050221429A1
(en)
*
|
2004-01-16 |
2005-10-06 |
Cardinal Health Pts, Llc |
Host cells containing multiple integrating vectors comprising an amplifiable marker
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
WO2005070948A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
|
CA2553828A1
(en)
*
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
DK1734814T3
(en)
*
|
2004-03-17 |
2015-04-07 |
Revivicor Inc |
Tissue DERIVED FROM ANIMALS IS MISSING ANY EXPRESSION OF FUNCTIONAL ALPHA-1,3 galactosyltransferase
|
CN104292321A
(zh)
|
2004-03-29 |
2015-01-21 |
株式会社嘉尔药物 |
新的半乳凝素9 突变体蛋白质及其用途
|
US20050223202A1
(en)
*
|
2004-03-31 |
2005-10-06 |
Intel Corporation |
Branch prediction in a pipelined processor
|
EP1732614B1
(de)
*
|
2004-04-08 |
2008-12-24 |
Sangamo Biosciences Inc. |
Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
|
CA2561565C
(en)
*
|
2004-04-08 |
2013-11-26 |
Sangamo Biosciences, Inc. |
Methods for repression of phospholamban gene and modulating cardiac contractility
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
WO2006020684A2
(en)
|
2004-08-10 |
2006-02-23 |
Institute For Multiple Myeloma And Bone Cancer Research |
Methods of regulating differentiation and treating of multiple myeloma
|
WO2006020996A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Cedars-Sinai Medical Center |
Treatment of parkinson's disease and related disorders
|
WO2006020949A2
(en)
|
2004-08-12 |
2006-02-23 |
Cedars-Sinai Medical Center |
Combined gene therapy for the treatment of macroscopic gliomas
|
AU2005287278B2
(en)
|
2004-09-16 |
2011-08-04 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
EP1793849A2
(de)
|
2004-09-22 |
2007-06-13 |
GlaxoSmithKline Biologicals SA |
Immunogene zusammensetzung zur verwendung bei der impfung gegen staphylokokken
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
AU2005287855B2
(en)
|
2004-09-24 |
2011-06-16 |
Mesoblast, Inc. |
Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
|
ES2710099T3
(es)
|
2004-09-24 |
2019-04-23 |
Mesoblast Inc |
Progenie de células precursoras mesenquimales expandidas multipotenciales (MEMP) y sus usos
|
PL2572661T3
(pl)
|
2004-10-05 |
2020-06-01 |
Genzyme Corporation |
Stopniowana kaniula
|
US7879321B2
(en)
*
|
2004-10-08 |
2011-02-01 |
Virxsys Corporation |
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
CN101124328A
(zh)
*
|
2004-12-15 |
2008-02-13 |
北卡罗来纳查佩尔山大学 |
嵌合载体
|
AU2006216671A1
(en)
*
|
2005-02-23 |
2006-08-31 |
The Uab Research Foundation |
Alkyl-glycoside enhanced vaccination
|
WO2006094106A2
(en)
*
|
2005-02-28 |
2006-09-08 |
Sangamo Biosciences, Inc. |
Anti-angiogenic methods and compositions
|
SG10201912554TA
(en)
|
2005-03-23 |
2020-02-27 |
Genmab As |
Antibodies against cd38 for treatment of multiple myeloma
|
JP5462483B2
(ja)
|
2005-04-12 |
2014-04-02 |
メゾブラスト,インコーポレーテッド |
組織非特異的アルカリホスファターゼによる成体多能性細胞の単離
|
WO2006113209A1
(en)
*
|
2005-04-15 |
2006-10-26 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
|
ES2696824T3
(es)
|
2005-05-31 |
2019-01-18 |
Univ Colorado Regents |
Métodos para suministrar genes
|
WO2006132925A2
(en)
*
|
2005-06-01 |
2006-12-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
|
US20060275812A1
(en)
*
|
2005-06-01 |
2006-12-07 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Assay for agonists and antagonists of ion channels and for regulators of genetic expression
|
KR101419729B1
(ko)
*
|
2005-07-26 |
2014-07-17 |
상가모 바이오사이언스 인코포레이티드 |
외래 핵산 서열의 표적화된 통합 및 발현
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
WO2007021886A2
(en)
*
|
2005-08-10 |
2007-02-22 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 for use for treating alzheimer's disease
|
US7858590B2
(en)
*
|
2005-08-11 |
2010-12-28 |
Cedars-Sinai Medical Center |
Treatment of parkinson's disease and related disorders
|
WO2007046703A2
(en)
|
2005-10-20 |
2007-04-26 |
Amsterdam Molecular Therapeutics B.V. |
Improved aav vectors produced in insect cells
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
US20070134204A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Henrich Cheng |
Method for treating nerve injury and vector construct for the same
|
WO2007071789A1
(en)
|
2005-12-22 |
2007-06-28 |
Vib Vzw |
Means and methods for mediating protein interference
|
US8669418B2
(en)
|
2005-12-22 |
2014-03-11 |
Vib Vzw |
Means and methods for mediating protein interference
|
US20090081157A1
(en)
|
2006-01-09 |
2009-03-26 |
Richard Syd Kornbluth |
Immunostimulatory Combinations for Vaccine Adjuvants
|
CA2648086C
(en)
|
2006-03-29 |
2014-05-13 |
Dana Farber Cancer Institute, Inc. |
Methods and compositions for inducing an immune response to hiv and models for testing
|
US20090017062A1
(en)
*
|
2006-04-28 |
2009-01-15 |
Iowa Research Foundation Iowa Centers For Enterpri |
Methods and compounds to alter virus infection
|
JP2009537140A
(ja)
*
|
2006-05-19 |
2009-10-29 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
ジヒドロ葉酸還元酵素の不活性化のための方法及び組成物
|
CA2651494C
(en)
*
|
2006-05-25 |
2015-09-29 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
EP3023500B1
(de)
|
2006-06-21 |
2020-02-12 |
uniQure IP B.V. |
Insektenzellen für die produktion von aav-vektoren
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
WO2008011344A2
(en)
*
|
2006-07-17 |
2008-01-24 |
Nationwide Children's Hospital Inc. |
Disruption of programmed death-1 (pd-1) ligands to adjuvant adeno-associated virus vector vaccines
|
RU2500815C2
(ru)
|
2006-07-28 |
2013-12-10 |
Санофи-Авентис |
Композиция и способ лечения опухолей
|
BRPI0715703A2
(pt)
|
2006-08-22 |
2013-09-17 |
G2 Inflammation Pty Ltd |
anticorpos anti-c5ar com propriedades melhoradas
|
ATE553206T1
(de)
*
|
2006-08-24 |
2012-04-15 |
Virovek Inc |
Expression von genen mit überlappenden offenen leserastern in insektenzellen, verfahren und zusammensetzungen dafür
|
WO2008060813A2
(en)
|
2006-10-19 |
2008-05-22 |
Merck & Co., Inc. |
High affinity antibody antagonists of interleukin-13 receptor alpha 1
|
ES2388567T3
(es)
|
2006-10-19 |
2012-10-16 |
Csl Limited |
Anticuerpos anti-il-13r alfa 1 y usos de los mismos
|
WO2008066658A2
(en)
|
2006-11-03 |
2008-06-05 |
The Trustees Of Princeton University |
Engineered cellular pathways for programmed autoregulation of differentiation
|
US20080113915A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Duke University |
SAPAP3 knockout mouse and clinical modeling associated with the SAPAP3 gene
|
CA2693178C
(en)
*
|
2006-11-29 |
2018-12-04 |
Nationwide Children's Hospital, Inc. |
Myostatin inhibition for enhancing muscle and/or improving muscle function
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
WO2008095027A2
(en)
*
|
2007-01-30 |
2008-08-07 |
Cedars-Sinai Medical Center |
Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
|
CN101678082B
(zh)
|
2007-03-26 |
2013-06-19 |
再生医药有限公司 |
使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
|
CN102268458B
(zh)
*
|
2007-04-23 |
2013-04-03 |
深圳益世康宁生物科技有限公司 |
一种ba46重组腺相关病毒载体及其构建方法与应用
|
WO2008134646A2
(en)
|
2007-04-26 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna interference suppression of neurodegenerative diseases and methods of use thereof
|
EP2530152B1
(de)
*
|
2007-05-31 |
2017-12-27 |
University of Iowa Research Foundation |
Reduktion der Off-Target-RNA-Interferenztoxizität
|
AU2008275649B2
(en)
|
2007-07-12 |
2013-09-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
|
TWI603736B
(zh)
|
2007-08-06 |
2017-11-01 |
安吉歐公司 |
活體內產生、修補及/或維持結締組織的方法
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
PL2612868T3
(pl)
|
2007-11-01 |
2018-12-31 |
Astellas Pharma Inc. |
Immunosupresyjne polipeptydy i kwasy nukleinowe
|
AU2009217224B2
(en)
|
2008-02-20 |
2014-09-11 |
G2 Inflammation Pty Ltd |
Humanized anti-C5aR antibodies
|
KR101794638B1
(ko)
|
2008-06-10 |
2017-12-04 |
상가모 테라퓨틱스, 인코포레이티드 |
Bax- 및 bak-결함 세포주들의 제조 방법 및 조성물
|
ES2872337T3
(es)
|
2008-06-25 |
2021-11-02 |
Mesoblast Inc |
Células STRO-1bright para su uso en el tratamiento del dolor de espalda baja
|
AU2009284692B2
(en)
|
2008-08-18 |
2016-02-25 |
Mesoblast, Inc. |
Monoclonal antibody STRO-4
|
US8703489B2
(en)
|
2008-08-22 |
2014-04-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
NO2356135T3
(de)
|
2008-11-05 |
2018-03-24 |
|
|
KR102011609B1
(ko)
|
2008-11-20 |
2019-08-16 |
메소블라스트, 아이엔씨. |
췌장 기능장애를 치료 또는 예방하는 방법
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
CN102307477B
(zh)
|
2009-01-05 |
2015-07-29 |
埃皮托吉尼西斯股份有限公司 |
佐剂组合物及使用方法
|
CA2751266A1
(en)
|
2009-01-29 |
2010-08-05 |
Krystof Bankiewicz |
Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
|
US8551945B2
(en)
|
2009-02-04 |
2013-10-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
US8889641B2
(en)
|
2009-02-11 |
2014-11-18 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
CA2755870C
(en)
|
2009-03-20 |
2019-04-09 |
Angioblast Systems, Inc. |
Production of reprogrammed pluripotent cells
|
CN102448501A
(zh)
|
2009-03-27 |
2012-05-09 |
西马生物医学计划公司 |
治疗肝硬化和肝纤维化的方法和组合物
|
CA2756833C
(en)
|
2009-04-09 |
2019-11-19 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
EP3421603B1
(de)
|
2009-05-02 |
2021-10-06 |
Genzyme Corporation |
Gentherapie für neurodegenerative erkrankungen
|
WO2010148010A1
(en)
|
2009-06-15 |
2010-12-23 |
4S3 Bioscience Inc. |
Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides
|
US20110300205A1
(en)
|
2009-07-06 |
2011-12-08 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
BR112012001666A2
(pt)
|
2009-07-15 |
2019-09-24 |
Novartis Ag |
composições de proteína rsv f e métodos para fazer as mesmas
|
WO2011016840A2
(en)
|
2009-07-28 |
2011-02-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating trinucleotide repeat disorders
|
EP2491116A4
(de)
|
2009-10-22 |
2013-12-11 |
Univ Jefferson |
Zellbasierte antikrebszusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
|
EP2497830A1
(de)
|
2009-11-05 |
2012-09-12 |
Proyecto de Biomedicina Cima, S.L. |
Regulierte expressionssysteme
|
EP2615106B1
(de)
|
2010-02-08 |
2018-04-25 |
Sangamo Therapeutics, Inc. |
Manipulierte Spaltungs-Halbdomänen
|
CA2788850C
(en)
|
2010-02-09 |
2019-06-25 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
WO2011106705A2
(en)
|
2010-02-26 |
2011-09-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Dna-protein vaccination protocols
|
EP3502254A1
(de)
|
2010-04-23 |
2019-06-26 |
Cold Spring Harbor Laboratory |
Neuartige strukturell designte shrnas
|
CA2798988C
(en)
|
2010-05-17 |
2020-03-10 |
Sangamo Biosciences, Inc. |
Tal-effector (tale) dna-binding polypeptides and uses thereof
|
EP2593115A4
(de)
|
2010-07-02 |
2013-12-04 |
Mesoblast Inc |
Behandlung von t-zellen-vermittelten immunstörungen
|
WO2012015938A2
(en)
|
2010-07-27 |
2012-02-02 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
WO2012025873A2
(en)
|
2010-08-23 |
2012-03-01 |
Wyeth Llc |
STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
|
PE20140173A1
(es)
|
2010-09-10 |
2014-02-20 |
Wyeth Llc |
Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
|
EP2622090B1
(de)
|
2010-09-27 |
2019-06-19 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur hemmung des eindringens von viren in zellen
|
BR112013008700B8
(pt)
|
2010-10-11 |
2022-10-04 |
Novartis Ag |
Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
|
EP2627359B1
(de)
|
2010-10-15 |
2015-12-30 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Expressionsvektor für 24-hydrolase zur behandlungder huntington-krankheit
|
CN103476456B
(zh)
|
2010-11-05 |
2017-10-03 |
斯坦福大学托管董事会 |
奖赏相关行为的光遗传学控制
|
ES2716819T3
(es)
|
2010-11-05 |
2019-06-17 |
Univ Leland Stanford Junior |
Opsinas quiméricas activadas por luz y métodos de uso de las mismas
|
JP2013544600A
(ja)
|
2010-11-23 |
2013-12-19 |
プレサージュ バイオサイエンシズ,インコーポレイテッド |
固体デリバリーのための治療方法および組成物
|
SI2667892T1
(sl)
|
2011-01-26 |
2019-05-31 |
Glaxosmithkline Biologicals Sa |
Imunizacijski režim proti RSV
|
US9181544B2
(en)
|
2011-02-12 |
2015-11-10 |
University Of Iowa Research Foundation |
Therapeutic compounds
|
WO2012142526A1
(en)
|
2011-04-14 |
2012-10-18 |
Modiano Jaime |
Use of tumor fas expression to determine response to anti-cancer therapy
|
US20140155469A1
(en)
|
2011-04-19 |
2014-06-05 |
The Research Foundation Of State University Of New York |
Adeno-associated-virus rep sequences, vectors and viruses
|
CA2839773C
(en)
|
2011-04-21 |
2021-03-30 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
US10196636B2
(en)
|
2011-04-21 |
2019-02-05 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
ES2651143T3
(es)
|
2011-05-13 |
2018-01-24 |
Glaxosmithkline Biologicals Sa |
Antígenos de F de prefusión del VRS
|
EP2714058B1
(de)
|
2011-06-03 |
2018-12-19 |
Mesoblast, Inc. |
Verfahren zur behandlung der folgen eines schlaganfalls
|
DK2718322T3
(en)
|
2011-06-06 |
2018-12-03 |
Novo Nordisk As |
THERAPEUTIC ANTIBODIES
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
WO2012177595A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
CA2839507A1
(en)
|
2011-06-24 |
2012-12-27 |
Epitogenesis Inc. |
Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
|
CN110051693A
(zh)
|
2011-07-04 |
2019-07-26 |
麦瑟布莱斯特公司 |
治疗或预防风湿性疾病的方法
|
WO2013012674A1
(en)
|
2011-07-15 |
2013-01-24 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
WO2013016352A1
(en)
|
2011-07-25 |
2013-01-31 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
US20140373187A1
(en)
|
2011-08-26 |
2014-12-18 |
Yecuris Corporation |
Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof
|
CN103857401B
(zh)
|
2011-09-09 |
2018-06-05 |
麦瑟布莱斯特公司 |
增加成骨细胞功能的方法
|
WO2013044008A2
(en)
|
2011-09-21 |
2013-03-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
CA2872033A1
(en)
|
2011-10-11 |
2013-04-18 |
Novartis Ag |
Recombinant self-replicating polycistronic rna molecules
|
US20140348863A1
(en)
|
2011-10-12 |
2014-11-27 |
Alessia Bianchi |
Cmv antigens and uses thereof
|
CN104321069A
(zh)
|
2011-10-27 |
2015-01-28 |
威尔斯达眼科制剂公司 |
编码视杆细胞来源的视锥细胞活力因子的载体
|
EP2771455B1
(de)
*
|
2011-10-28 |
2016-10-05 |
The University of North Carolina At Chapel Hill |
Zelllinie zur produktion eines adenoassoziierten virus
|
US9434928B2
(en)
|
2011-11-23 |
2016-09-06 |
Nationwide Children's Hospital, Inc. |
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
|
US9365628B2
(en)
|
2011-12-16 |
2016-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Opsin polypeptides and methods of use thereof
|
WO2013126521A1
(en)
|
2012-02-21 |
2013-08-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for treating neurogenic disorders of the pelvic floor
|
CA2865011C
(en)
|
2012-02-29 |
2021-06-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
SG10201602558UA
(en)
|
2012-03-09 |
2016-05-30 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
CA2875683A1
(en)
|
2012-06-05 |
2013-12-12 |
The Australian National University |
Vaccination with interleukin-4 antagonists
|
JP2015523998A
(ja)
|
2012-06-19 |
2015-08-20 |
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド |
疾患を治療するための組成物および方法
|
US10883119B2
(en)
|
2012-07-11 |
2021-01-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for delivery of biologics
|
HUE051612T2
(hu)
|
2012-07-11 |
2021-03-01 |
Sangamo Therapeutics Inc |
Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
|
CA2880811C
(en)
|
2012-08-01 |
2021-12-07 |
United Therapeutics Corporation |
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
|
ES2684222T3
(es)
|
2012-08-01 |
2018-10-01 |
Nationwide Children's Hospital |
Administración intratecal de virus adenoasociado 9 recombinante
|
CA2880808C
(en)
|
2012-08-01 |
2023-01-24 |
United Therapeutics Corporation |
Treatment of pulmonary arterial hypertension with mesenchymal stem cells
|
CN104704110B
(zh)
|
2012-08-29 |
2018-06-01 |
桑格摩生物科学股份有限公司 |
用于治疗遗传性病状的方法和组合物
|
WO2014043696A2
(en)
|
2012-09-17 |
2014-03-20 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating amyotrophic lateral sclerosis
|
ES2824024T3
(es)
|
2012-10-10 |
2021-05-11 |
Sangamo Therapeutics Inc |
Compuestos modificadores de células T y usos de los mismos
|
EP3789405A1
(de)
|
2012-10-12 |
2021-03-10 |
The General Hospital Corporation |
Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
|
EP2922476B1
(de)
|
2012-11-21 |
2019-10-09 |
Circuit Therapeutics, Inc. |
System für optogenetische therapie
|
US10272163B2
(en)
|
2012-12-07 |
2019-04-30 |
The Regents Of The University Of California |
Factor VIII mutation repair and tolerance induction
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
EP2931899A1
(de)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Funktionale genomik unter verwendung von crispr-cas systemen, zusammensetzungen, verfahren, knockout-bibliotheken und anwendungen davon
|
SG10201705061RA
(en)
|
2012-12-12 |
2017-07-28 |
Mesoblast Inc |
Treatment of Diseases of Endothelial Dysfunction and Inflammation
|
EP2932421A1
(de)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Verfahren, systeme und vorrichtung zur identifizierung von zielsequenzen für cas-enzyme oder crispr-cas-systeme für zielsequenzen und ergebnisübermittlung
|
CN113528577A
(zh)
|
2012-12-12 |
2021-10-22 |
布罗德研究所有限公司 |
用于序列操纵的系统、方法和优化的指导组合物的工程化
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
ES2883590T3
(es)
|
2012-12-12 |
2021-12-09 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
|
EP4234696A3
(de)
|
2012-12-12 |
2023-09-06 |
The Broad Institute Inc. |
Systeme, verfahren und zusammensetzungen mit crispr-cas-komponenten zur sequenzmanipulation
|
JP6552965B2
(ja)
|
2012-12-12 |
2019-07-31 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
配列操作のための改善された系、方法および酵素組成物のエンジニアリングおよび最適化
|
ES2576128T3
(es)
|
2012-12-12 |
2016-07-05 |
The Broad Institute, Inc. |
Modificación por tecnología genética y optimización de sistemas, métodos y composiciones para la manipulación de secuencias con dominios funcionales
|
JP6534933B2
(ja)
|
2013-01-08 |
2019-06-26 |
ジェンザイム・コーポレーション |
培養物中のウイルス収量を増加させるためのiNOS阻害剤の使用
|
EP3415150B1
(de)
|
2013-01-09 |
2021-08-18 |
United Therapeutics Corporation |
Behandlung von vaskulopathie mit prostacyclin und mesenchymalen stammzellen
|
US9066966B2
(en)
|
2013-02-01 |
2015-06-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
|
WO2014120975A1
(en)
|
2013-02-01 |
2014-08-07 |
California Institute Of Technology |
Antibody-mediated immunocontraception
|
CA2901978A1
(en)
|
2013-02-20 |
2014-08-28 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of pompe disease
|
EP2964665B1
(de)
|
2013-03-08 |
2018-08-01 |
Pfizer Inc |
Immunogene fusionspolypeptide
|
EP2968613B1
(de)
|
2013-03-11 |
2019-09-11 |
University of Florida Research Foundation, Inc. |
Freisetzung von card-protein zur behandlung von augenentzündungen
|
WO2014144844A1
(en)
|
2013-03-15 |
2014-09-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
|
MX371272B
(es)
|
2013-03-15 |
2020-01-22 |
Univ California |
El péptido mots3 derivado de mitocondrias regula el metabolismo y la supervivencia celular.
|
EP2968997B1
(de)
|
2013-03-15 |
2019-06-26 |
The Board of Trustees of the Leland Stanford Junior University |
Optogenetische steuerung des verhaltenszustandes
|
US9644215B2
(en)
|
2013-04-12 |
2017-05-09 |
The General Hospital Corporation |
AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors
|
EP3741385A1
(de)
|
2013-04-17 |
2020-11-25 |
Genzyme Corporation |
Zusammensetzungen zur anwendung in einem verfahren zur behandlung und vorbeugung von makuladegeneration
|
KR20230074604A
(ko)
|
2013-04-20 |
2023-05-30 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
엑손 2-표적 U7snRNA 폴리뉴클레오티드 작제물의 재조합형 아데노 부속 바이러스 전달
|
EP2991491B1
(de)
|
2013-04-29 |
2019-12-25 |
The Board of Trustees of the Leland Stanford Junior University |
Vorrichtungen, systeme und verfahren zur optogenetischen modulation von wirkungspotentialen in zielzellen
|
CA2910489A1
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
CA2915834A1
(en)
|
2013-06-17 |
2014-12-24 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
CN105492611A
(zh)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
|
RU2725502C2
(ru)
|
2013-06-17 |
2020-07-02 |
Те Брод Инститьют Инк. |
Доставка, конструирование и оптимизация систем, способы и композиции для целенаправленного воздействия и моделирования заболеваний и нарушений постмитотических клеток
|
EP3725885A1
(de)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Funktionale genomik unter verwendung von crispr-cas-systemen, zusammensetzungen, verfahren, schirme und anwendungen davon
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
CN105793425B
(zh)
|
2013-06-17 |
2021-10-26 |
布罗德研究所有限公司 |
使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
CN105829538A
(zh)
|
2013-08-14 |
2016-08-03 |
小利兰·斯坦福大学托管委员会 |
用于控制疼痛的组合物和方法
|
ES2936220T3
(es)
|
2013-08-27 |
2023-03-15 |
Res Inst Nationwide Childrens Hospital |
Productos y métodos para el tratamiento de la esclerosis lateral amiotrófica
|
EP3988654A1
(de)
|
2013-08-28 |
2022-04-27 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur vernetzung von dna-bindungsdomänen und -spaltungsdomänen
|
EP3039129B1
(de)
|
2013-08-30 |
2018-06-27 |
Amgen Inc. |
Herstellung rekombinanter aav-vektoren mit hohem titer in haftenden und hängenden zellen
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
CA2926094C
(en)
|
2013-10-17 |
2024-04-02 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
EP3066203B2
(de)
|
2013-11-05 |
2023-11-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues tiermodell für die alzheimer-krankheit
|
EP3065784A4
(de)
|
2013-11-05 |
2017-05-10 |
The Research Institute at Nationwide Children's Hospital |
Zusammensetzungen und verfahren zur hemmung von nf-kb und sod-1 zur behandlung von amyotropher lateralsklerose
|
BR112016010175A2
(pt)
|
2013-11-11 |
2017-10-03 |
Sangamo Biosciences Inc |
Repressor genético, seus usos, e composição farmacêutica
|
SI3068881T1
(sl)
|
2013-11-13 |
2019-05-31 |
Children's Medical Center Corporation |
Z nukleazo posredovano uravnavanje izražanja genov
|
EP3068783B1
(de)
|
2013-11-15 |
2020-09-23 |
The Board of Trustees of the Leland Stanford Junior University |
Agonisten des hypokretin-rezeptors 2 zur verwendung zur behandlung von herzversagen
|
ES2813367T3
(es)
|
2013-12-09 |
2021-03-23 |
Sangamo Therapeutics Inc |
Métodos y composiciones para ingeniería genómica
|
AU2014361781B2
(en)
|
2013-12-12 |
2021-04-01 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
BR112016013207A2
(pt)
|
2013-12-12 |
2017-09-26 |
Massachusetts Inst Technology |
administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
|
MX2016007327A
(es)
|
2013-12-12 |
2017-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para dirigirlos a trastornos y enfermedades usando componentes para suministro de particulas.
|
HUE051232T2
(hu)
|
2014-02-03 |
2021-03-01 |
Sangamo Therapeutics Inc |
Béta-talasszémia kezelésére szolgáló eljárások és készítmények
|
JP6719381B2
(ja)
|
2014-02-06 |
2020-07-08 |
ジェンザイム・コーポレーション |
黄斑変性を処置し、予防するための組成物および方法
|
US11053291B2
(en)
|
2014-02-19 |
2021-07-06 |
University Of Florida Research Foundation, Incorporated |
Delivery of Nrf2 as therapy for protection against reactive oxygen species
|
WO2015124546A1
(en)
|
2014-02-19 |
2015-08-27 |
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic |
Aav vectors for the treatment of ischemic and non-ischemic heart disease
|
WO2015143046A2
(en)
|
2014-03-18 |
2015-09-24 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
KR102417915B1
(ko)
|
2014-03-21 |
2022-07-07 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
뉴클레아제 없는 게놈 편집
|
WO2015148974A2
(en)
|
2014-03-28 |
2015-10-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered light-activated anion channel proteins and methods of use thereof
|
BR112016025849A2
(pt)
|
2014-05-08 |
2017-10-17 |
Chdi Foundation Inc |
métodos e composições para o tratamento da doença de huntington
|
CA2949437C
(en)
|
2014-05-20 |
2023-08-15 |
University Of Iowa Research Foundation |
Huntington's disease therapeutic compounds
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
MX2016016833A
(es)
|
2014-06-16 |
2017-10-04 |
Univ Johns Hopkins |
Composiciones y metodos para la expresion de arns guias crispr que usan el promotor h1.
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
KR102330593B1
(ko)
|
2014-07-28 |
2021-11-26 |
에스케이이노베이션 주식회사 |
신규 이소프렌 신타아제 및 이를 이용한 이소프렌의 제조방법
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
CA2957661A1
(en)
|
2014-08-09 |
2016-02-18 |
Kevin FLANIGAN |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
WO2016028682A1
(en)
|
2014-08-17 |
2016-02-25 |
The Broad Institute Inc. |
Genome editing using cas9 nickases
|
RS62334B1
(sr)
|
2014-09-16 |
2021-10-29 |
Sangamo Therapeutics Inc |
Postupci i sastavi za inženjering genoma posredovan nukleazom i korekciju kod matičnih ćelija hematopoeze
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
US10842886B2
(en)
|
2014-10-10 |
2020-11-24 |
Research Institute At Nationwide Children's Hospital |
Guided injections for AAV gene transfer to muscle
|
JP6401871B2
(ja)
|
2014-11-05 |
2018-10-10 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
パーキンソン病の治療のためのaadcポリヌクレオチド
|
EP3690024A1
(de)
|
2014-11-05 |
2020-08-05 |
The Research Institute at Nationwide Children's Hospital |
Verfahren und materialien zur herstellung rekombinanter viren in eukaryotischen mikroalgen
|
EP3218484A4
(de)
|
2014-11-14 |
2018-05-30 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als)
|
SG11201703419UA
(en)
|
2014-11-14 |
2017-05-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
EP3230441A4
(de)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur herstellung von scaav
|
EP3230452A1
(de)
|
2014-12-12 |
2017-10-18 |
The Broad Institute Inc. |
Totführungen für crispr-transkriptionsfaktoren
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
EP3985115A1
(de)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Geschützte guide-rnas (pgrnas)
|
SG11201704690TA
(en)
|
2014-12-17 |
2017-07-28 |
Fundación Para La Investigación Mèdica Aplicada |
Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease
|
ES2784264T3
(es)
|
2014-12-17 |
2020-09-23 |
Fundacion Para La Investig Medica Aplicada |
Construcciones de ácido nucleico y vectores de terapia génica para su uso en el tratamiento de la enfermedad de Wilson y otras afecciones
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
WO2016106244A1
(en)
|
2014-12-24 |
2016-06-30 |
The Broad Institute Inc. |
Crispr having or associated with destabilization domains
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
EP3054006A1
(de)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Reinigung von rekombinanten adeno-assoziierten viruspartikeln mittels mehrstufiger anionischer austauschchromatografie
|
EP3054007A1
(de)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
|
BR112017017460A2
(pt)
|
2015-02-19 |
2018-04-10 |
Pfizer Inc. |
composições de neisseria meningitidis e métodos das mesmas
|
BR112017017812A2
(pt)
|
2015-02-23 |
2018-04-10 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de hemoglobinopatias
|
WO2016154010A1
(en)
|
2015-03-20 |
2016-09-29 |
Makidon Paul |
Immunogenic compositions for use in vaccination against bordetella
|
US11040113B2
(en)
|
2015-03-23 |
2021-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia
|
MX2017012097A
(es)
|
2015-03-24 |
2018-06-15 |
Univ California |
Variantes de virus adenoasociado y métodos de uso de estas.
|
WO2016161446A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
ES2911266T3
(es)
|
2015-05-05 |
2022-05-18 |
Mesoblast Int Sarl |
Ensayo de potencia
|
ES2959642T3
(es)
|
2015-05-13 |
2024-02-27 |
The Us Secretary Of The Department Of Health And Human Services |
Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
US20180161395A1
(en)
|
2015-06-12 |
2018-06-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical composition for the treatment of alzheimer's disease
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
FI3430134T3
(fi)
|
2015-06-18 |
2023-01-13 |
|
Uusia CRISPR-entsyymejä ja järjestelmiä
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
US10550379B2
(en)
|
2015-06-29 |
2020-02-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Degron fusion constructs and methods for controlling protein production
|
WO2017005806A1
(en)
|
2015-07-07 |
2017-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject
|
CN108024544B
(zh)
|
2015-07-13 |
2022-04-29 |
桑格摩生物治疗股份有限公司 |
用于核酸酶介导的基因组工程化的递送方法及组合物
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US10017832B2
(en)
|
2015-08-25 |
2018-07-10 |
Washington University |
Compositions and methods for site specific recombination at asymmetric sites
|
US10980897B2
(en)
|
2015-09-17 |
2021-04-20 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for GALGT2 gene therapy
|
CA2998287A1
(en)
|
2015-09-24 |
2017-04-20 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
CA3024543A1
(en)
|
2015-10-22 |
2017-04-27 |
The Broad Institute, Inc. |
Type vi-b crispr enzymes and systems
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したCas9蛋白質
|
JP2019507579A
(ja)
|
2015-10-28 |
2019-03-22 |
クリスパー セラピューティクス アーゲー |
デュシェンヌ型筋ジストロフィーの処置のための材料および方法
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
US10377801B2
(en)
|
2015-11-04 |
2019-08-13 |
Northwestern University |
Amelioration of chronic kidney disease
|
BR112018008971A2
(pt)
|
2015-11-06 |
2018-11-27 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
|
BR112018009954A2
(pt)
|
2015-11-16 |
2018-11-13 |
Res Inst Nationwide Childrens Hospital |
materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias
|
US10669320B2
(en)
|
2015-11-18 |
2020-06-02 |
The Regents Of The University Of Michigan |
Mps1 and KNL1 phosphorylation system
|
WO2017093804A2
(en)
|
2015-12-01 |
2017-06-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
US10406244B2
(en)
|
2015-12-02 |
2019-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
AAV vectors with expanded packaging capacity
|
US10385320B2
(en)
|
2015-12-02 |
2019-08-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
|
CN108699132B
(zh)
|
2015-12-18 |
2023-08-11 |
桑格摩生物治疗股份有限公司 |
Mhc细胞受体的靶向破坏
|
US20190233814A1
(en)
|
2015-12-18 |
2019-08-01 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
JP7128741B2
(ja)
|
2015-12-18 |
2022-08-31 |
サンガモ セラピューティクス, インコーポレイテッド |
T細胞受容体の標的化破壊
|
CA3009308A1
(en)
|
2015-12-23 |
2017-06-29 |
Chad Albert COWAN |
Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
|
WO2017120589A1
(en)
|
2016-01-08 |
2017-07-13 |
Washington University |
Compositions comprising chemerin and methods of use thereof
|
WO2017123757A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
PT3405215T
(pt)
|
2016-01-19 |
2022-09-20 |
Univ California |
Métodos para o tratamento da doença de danon e outros transtornos da autofagia
|
CA3011049A1
(en)
|
2016-02-02 |
2017-08-10 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
US20190038771A1
(en)
|
2016-02-02 |
2019-02-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
WO2017139381A1
(en)
|
2016-02-08 |
2017-08-17 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
WO2017143100A1
(en)
|
2016-02-16 |
2017-08-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
|
EP3416689B1
(de)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn syndrome
|
WO2017147509A1
(en)
|
2016-02-25 |
2017-08-31 |
Marco Colonna |
Compositions comprising trem2 and methods of use thereof
|
JP6966463B2
(ja)
|
2016-02-26 |
2021-11-17 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
組換えウイルス産物及びdux4エクソンスキッピングを誘導するための方法
|
MX2018010842A
(es)
|
2016-03-07 |
2019-07-04 |
Univ Iowa Res Found |
Expresion mediada por el virus adeno-asociado (aav) usando un promotor y pontenciador sintetico.
|
WO2017158422A1
(en)
|
2016-03-16 |
2017-09-21 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hereditary haemochromatosis
|
BR112018069703A2
(pt)
|
2016-03-28 |
2019-02-05 |
Dimension Therapeutics Inc |
métodos de inativação de adenovírus por calor
|
ES2896080T3
(es)
|
2016-03-31 |
2022-02-23 |
Spark Therapeutics Inc |
Procedimiento en columna totalmente escalable de preparación de VAAr
|
CA3019832C
(en)
|
2016-04-02 |
2023-05-09 |
Research Institute At Nationwide Children's Hospital |
Modified u6 promoter system for tissue specific expression
|
MA45477A
(fr)
|
2016-04-15 |
2019-02-20 |
Res Inst Nationwide Childrens Hospital |
Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
|
CA3021057A1
(en)
|
2016-04-15 |
2017-10-19 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy
|
US20200330609A1
(en)
|
2016-04-18 |
2020-10-22 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
CA3026110A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
AU2017253107B2
(en)
|
2016-04-19 |
2023-07-20 |
Massachusetts Institute Of Technology |
CPF1 complexes with reduced indel activity
|
KR102424476B1
(ko)
|
2016-04-19 |
2022-07-25 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3448874A4
(de)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
WO2017201258A1
(en)
|
2016-05-18 |
2017-11-23 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
EP3458588A4
(de)
|
2016-05-18 |
2020-01-15 |
Voyager Therapeutics, Inc. |
Modulatorische polynukleotide
|
WO2018229521A1
(en)
|
2016-06-16 |
2018-12-20 |
Oslo Universitetssykehus Hf |
Improved gene editing
|
EP3455357A1
(de)
|
2016-06-17 |
2019-03-20 |
The Broad Institute Inc. |
Typ-vi-crispr-orthologe und systeme
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
CA3029119A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
US11174469B2
(en)
|
2016-06-29 |
2021-11-16 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
|
CN109844116A
(zh)
|
2016-07-05 |
2019-06-04 |
约翰霍普金斯大学 |
包括使用h1启动子对crispr指导rna的改进的组合物和方法
|
JP2019520079A
(ja)
|
2016-07-06 |
2019-07-18 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
疼痛関連障害を処置するための物質及び方法
|
CA3029132A1
(en)
|
2016-07-06 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of pain related disorders
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
US11124805B2
(en)
|
2016-07-13 |
2021-09-21 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
WO2018013932A1
(en)
|
2016-07-15 |
2018-01-18 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
WO2018018082A1
(en)
|
2016-07-26 |
2018-02-01 |
The Australian National University |
Immunostimulatory compositions and uses therefor
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
US10696722B2
(en)
|
2016-08-10 |
2020-06-30 |
Ajou University Industry-Academic Cooperation Foundation |
Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
|
US20200283743A1
(en)
|
2016-08-17 |
2020-09-10 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
MX2019002207A
(es)
|
2016-08-24 |
2019-07-15 |
Sangamo Therapeutics Inc |
Regulacion de la expresion genica usando nucleasas modificadas.
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
EP3831281A1
(de)
|
2016-08-30 |
2021-06-09 |
The Regents of The University of California |
Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
EP3526321A4
(de)
|
2016-10-14 |
2020-05-13 |
Ultragenyx Pharmaceutical Inc. |
Verwendung von tonifizierenden mitteln zur verbesserung der ausbeute von rekombinantem adeno-assoziiertem virus
|
BR112019007210A2
(pt)
|
2016-10-20 |
2019-08-13 |
Sangamo Therapeutics Inc |
métodos e composições para o tratamento da doença de fabry
|
ES2927406T3
(es)
|
2016-10-24 |
2022-11-04 |
United Therapeutics Corp |
Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil
|
CA3041668A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
EP3535293A1
(de)
|
2016-11-07 |
2019-09-11 |
Crossbeta Biosciences B.V. |
Neuartiges amyloid-beta-oligomerspezifisches bindungsmolekül
|
AU2017362491B2
(en)
|
2016-11-17 |
2023-02-02 |
Nationwide Children's Hospital Inc. |
Intrathecal delivery of recombinant Adeno-associated virus encoding Methyl-CpG binding protein 2
|
EP4276187A3
(de)
|
2016-12-08 |
2024-01-17 |
Case Western Reserve University |
Verfahren und zusammensetzungen zur erhöhung der herstellung von funktionalem myelin
|
AU2017378153B2
(en)
|
2016-12-13 |
2024-03-28 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
WO2018138360A1
(en)
|
2017-01-28 |
2018-08-02 |
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) |
Oxygen carrying blood substitutes and their use as delivery vehicles
|
WO2018138371A1
(en)
|
2017-01-30 |
2018-08-02 |
Brainvectis |
Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias
|
AU2018215585B2
(en)
|
2017-01-31 |
2022-03-17 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
US20200216857A1
(en)
|
2017-02-22 |
2020-07-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
WO2018154459A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
JP2020508056A
(ja)
|
2017-02-22 |
2020-03-19 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
遺伝子編集のための組成物および方法
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
KR20190127797A
(ko)
|
2017-03-10 |
2019-11-13 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
시토신에서 구아닌으로의 염기 편집제
|
JP2020513811A
(ja)
|
2017-03-17 |
2020-05-21 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達
|
MA47800A
(fr)
|
2017-03-17 |
2020-01-22 |
Univ Newcastle |
Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
|
US11898170B2
(en)
|
2017-03-22 |
2024-02-13 |
Ultragenyx Pharmaceutical Inc. |
Cell culture methods involving HDAC inhibitors or rep proteins
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
EP3600267A1
(de)
|
2017-03-24 |
2020-02-05 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von neurodegenerativer krankheit
|
US11773409B2
(en)
|
2017-04-21 |
2023-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors
|
CA3062112A1
(en)
|
2017-05-04 |
2018-11-08 |
Mesoblast International Sarl |
Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
|
WO2018204803A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
筋萎縮性側索硬化症(als)治療組成物および方法
|
US11872262B2
(en)
|
2017-05-09 |
2024-01-16 |
Vib Vzw |
Means and methods for treating bacterial infections
|
WO2018208910A1
(en)
|
2017-05-09 |
2018-11-15 |
The Broad Institute Inc. |
Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
JP7356354B2
(ja)
|
2017-05-12 |
2023-10-04 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
JP7136816B2
(ja)
|
2017-06-23 |
2022-09-13 |
インスクリプタ, インコーポレイテッド |
核酸誘導型ヌクレアーゼ
|
CN111328290A
(zh)
|
2017-06-26 |
2020-06-23 |
博德研究所 |
用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法
|
US10392616B2
(en)
|
2017-06-30 |
2019-08-27 |
Arbor Biotechnologies, Inc. |
CRISPR RNA targeting enzymes and systems and uses thereof
|
JP2020532284A
(ja)
|
2017-07-08 |
2020-11-12 |
ジェネトン |
脊髄性筋萎縮症の治療
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
US11497576B2
(en)
|
2017-07-17 |
2022-11-15 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
EP3808849A1
(de)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur aav-freisetzung
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
US20200297871A1
(en)
|
2017-09-15 |
2020-09-24 |
King's College London |
Compositions and methods for enhancing gamma delta t cells in the gut
|
AU2018338318B2
(en)
|
2017-09-21 |
2022-12-22 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
EP3688014A4
(de)
|
2017-09-29 |
2020-09-16 |
Massachusetts Eye and Ear Infirmary |
Herstellung von adeno-assoziierten viren in insektenzellen
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
AU2018352236A1
(en)
|
2017-10-16 |
2020-04-23 |
The Curators Of The University Of Missouri |
Treatment of amyotrophic lateral sclerosis (ALS)
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
US20220080055A9
(en)
|
2017-10-17 |
2022-03-17 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing for hemophilia a
|
MA50836A
(fr)
|
2017-10-18 |
2020-08-26 |
Res Inst Nationwide Childrens Hospital |
Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique de muscles pour traiter la dystrophie musculaire
|
KR20200083495A
(ko)
|
2017-10-20 |
2020-07-08 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
Nt-3 유전자 치료를 위한 방법 및 물질
|
US20210180091A1
(en)
|
2017-10-26 |
2021-06-17 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
US20210317474A1
(en)
|
2017-11-08 |
2021-10-14 |
Novartis Ag |
Means and method for producing and purifying viral vectors
|
MA50579A
(fr)
|
2017-11-09 |
2020-09-16 |
Crispr Therapeutics Ag |
Systèmes crispr/cas ou crispr/cpf1 à auto-inactivation (sin) et leurs utilisations
|
CA3082450A1
(en)
|
2017-11-21 |
2019-05-31 |
Crispr Therapeutics Ag |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
CA3083601A1
(en)
|
2017-11-28 |
2019-06-06 |
Mirimus, Inc. |
Methods of genetic mediated engineering of rnai models
|
CA3084825A1
(en)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
EP3728595A1
(de)
|
2017-12-21 |
2020-10-28 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
|
AU2018393050A1
(en)
|
2017-12-21 |
2020-06-18 |
Bayer Healthcare Llc |
Materials and methods for treatment of Usher Syndrome Type 2A
|
CA3088180A1
(en)
|
2018-01-12 |
2019-07-18 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting transferrin
|
KR20200109358A
(ko)
|
2018-01-17 |
2020-09-22 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제
|
IL276081B2
(en)
|
2018-01-17 |
2023-10-01 |
Vertex Pharma |
Quinoxalinone compounds, preparations, methods and kits for increasing the efficiency of genome editing
|
WO2019143678A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
US11268077B2
(en)
|
2018-02-05 |
2022-03-08 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
EP3749767A1
(de)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materialien und verfahren zur behandlung von hämoglobinopathien
|
MA51869A
(fr)
|
2018-02-16 |
2020-12-23 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique par ciblage du fibrinogène-alpha
|
WO2019160383A1
(ko)
|
2018-02-19 |
2019-08-22 |
고려대학교 산학협력단 |
열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
|
EP3755795A4
(de)
|
2018-02-19 |
2022-07-20 |
Homology Medicines, Inc. |
Adeno-assoziierte viruszusammensetzungen zur wiederherstellung der f8-genfunktion und verfahren zur verwendung davon
|
PT3765615T
(pt)
|
2018-03-14 |
2023-08-28 |
Arbor Biotechnologies Inc |
Novas enzimas e sistemas de direcionamento de dna crispr
|
DK3765616T3
(da)
|
2018-03-14 |
2023-08-21 |
Arbor Biotechnologies Inc |
Nye enzymer og systemer målrettet crispr dna og rna
|
WO2019175384A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
EP3765064A1
(de)
|
2018-03-16 |
2021-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pcsk2-abgeleitete antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1
|
US20210070819A1
(en)
|
2018-03-16 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
AU2019239957A1
(en)
|
2018-03-19 |
2020-09-10 |
Bayer Healthcare Llc |
Novel RNA-programmable endonuclease systems and uses thereof
|
WO2019191701A1
(en)
|
2018-03-30 |
2019-10-03 |
The Board Of Trustees Of Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
|
IT201800004253A1
(it)
|
2018-04-05 |
2019-10-05 |
|
Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
JP2021521852A
(ja)
|
2018-04-27 |
2021-08-30 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
Aadcウイルスベクターの効力を測定する方法
|
EP3794127A1
(de)
|
2018-05-14 |
2021-03-24 |
Vivet Therapeutics |
Gentherapeutische vektoren mit s/mar-sequenzen
|
CA3099306A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒(aav)之組成物和方法
|
EP3793615A2
(de)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Gerichtete entwicklung von aav zur verbesserung des tropismus für zns
|
WO2019222441A1
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
US20210198330A1
(en)
|
2018-05-23 |
2021-07-01 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
CA3102840A1
(en)
|
2018-06-05 |
2019-12-12 |
Lifeedit, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
KR20210018919A
(ko)
|
2018-06-08 |
2021-02-18 |
노파르티스 아게 |
약물 산물 효능을 측정하기 위한 세포-기반 분석
|
GB201809588D0
(en)
|
2018-06-12 |
2018-07-25 |
Univ Bristol |
Materials and methods for modulating intraocular and intracranial pressure
|
EP3807404A1
(de)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Manipulierte 5'-unübersetzte regionen (5' utr) zur herstellung von aav
|
US20210260218A1
(en)
|
2018-06-18 |
2021-08-26 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
AU2019288291A1
(en)
|
2018-06-18 |
2021-01-21 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
|
CN112543810A
(zh)
|
2018-06-29 |
2021-03-23 |
全国儿童医院研究所 |
治疗肢带型肌营养不良2a型的重组腺相关病毒产品和方法
|
JP2021529513A
(ja)
|
2018-07-02 |
2021-11-04 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
筋萎縮性側索硬化症および脊髄に関連する障害の治療
|
EP3820537A4
(de)
|
2018-07-12 |
2022-04-13 |
Spacecraft Seven, LLC |
Gentherapievektoren zur behandlung der danon-erkrankung
|
WO2020018142A1
(en)
|
2018-07-16 |
2020-01-23 |
Arbor Biotechnologies, Inc. |
Novel crispr dna targeting enzymes and systems
|
EP3826719A1
(de)
|
2018-07-24 |
2021-06-02 |
Voyager Therapeutics, Inc. |
Systeme und verfahren zur herstellung von gentherapieformulierungen
|
JP2021532815A
(ja)
|
2018-08-07 |
2021-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新規Cas12b酵素およびシステム
|
US20210317429A1
(en)
|
2018-08-20 |
2021-10-14 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
CN110857440B
(zh)
|
2018-08-23 |
2021-02-19 |
武汉纽福斯生物科技有限公司 |
重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
|
CA3110665A1
(en)
|
2018-08-29 |
2020-03-05 |
Research Institute At Nationwide Children's Hospital |
Products and methods for inhibition of expression of mutant gars protein
|
US20210317430A1
(en)
|
2018-09-18 |
2021-10-14 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
AU2019346655A1
(en)
|
2018-09-28 |
2021-05-06 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
SG11202103425YA
(en)
|
2018-10-05 |
2021-05-28 |
Voyager Therapeutics Inc |
Engineered nucleic acid constructs encoding aav production proteins
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
CA3116098A1
(en)
|
2018-10-12 |
2020-04-16 |
Vivet Therapeutics |
Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
|
WO2020079033A1
(en)
|
2018-10-15 |
2020-04-23 |
Fondazione Telethon |
Genome editing methods and constructs
|
WO2020081490A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
JP2022505173A
(ja)
|
2018-10-17 |
2022-01-14 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフト |
導入遺伝子を送達するための組成物および方法
|
SG11202103732RA
(en)
|
2018-10-18 |
2021-05-28 |
Intellia Therapeutics Inc |
Nucleic acid constructs and methods of use
|
BR112021007175A2
(pt)
|
2018-10-23 |
2021-08-10 |
Dragonfly Therapeutics, Inc. |
proteínas fundidas a fc heterodimérico
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
JP2022512838A
(ja)
|
2018-10-29 |
2022-02-07 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
筋萎縮性側索硬化症の治療におけるコレステロール24―ヒドロラーゼの発現ベクター
|
CN111118016B
(zh)
|
2018-10-30 |
2022-04-15 |
上海朗昇生物科技有限公司 |
治疗视网膜色素变性疾病的基因治疗载体
|
JP2022512930A
(ja)
|
2018-11-07 |
2022-02-07 |
ヴィヴェ テラピューティクス |
進行性家族性肝内胆汁鬱滞タイプ2(pfic2)の治療のためのコドン最適化abcb11導入遺伝子
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
TW202039859A
(zh)
|
2018-11-30 |
2020-11-01 |
美商艾夫西斯公司 |
Aav病毒載體及其用途
|
AU2019406778A1
(en)
|
2018-12-17 |
2021-07-22 |
Massachusetts Institute Of Technology |
Crispr-associated transposase systems and methods of use thereof
|
JP2022516010A
(ja)
|
2018-12-21 |
2022-02-24 |
ジェネトン |
遺伝子療法ベクターのための発現カセット
|
AU2019416108A1
(en)
|
2018-12-27 |
2021-08-12 |
LifeEDIT Therapeutics, Inc. |
Polypeptides useful for gene editing and methods of use
|
KR20210110345A
(ko)
|
2018-12-31 |
2021-09-07 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
RNA 표적화 CRISPR-Cas13b를 사용한 DUX4 RNA 침묵화
|
WO2020141473A1
(en)
|
2019-01-02 |
2020-07-09 |
Mesoblast International Sárl |
Method for treating lower back pain
|
AU2020204809A1
(en)
|
2019-01-03 |
2021-07-29 |
Mesoblast International Sàrl |
Method for improving visual acuity
|
US20220064671A1
(en)
|
2019-01-18 |
2022-03-03 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
MX2021009401A
(es)
|
2019-02-04 |
2021-11-12 |
Res Inst Nationwide Childrens Hospital |
Administracion de virus adenoasociado de polinucleotido de cln3.
|
KR20210124299A
(ko)
|
2019-02-04 |
2021-10-14 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
Cln6 폴리뉴클레오티드의 아데노-관련 바이러스 전달
|
WO2020168362A1
(en)
|
2019-02-15 |
2020-08-20 |
Crispr Therapeutics Ag |
Gene editing for hemophilia a with improved factor viii expression
|
WO2020172624A1
(en)
|
2019-02-22 |
2020-08-27 |
Life Technologies Corporation |
Suspension system for adeno associated virus production
|
CN113766935A
(zh)
|
2019-02-26 |
2021-12-07 |
全国儿童医院研究所 |
β-肌聚糖的腺相关病毒载体递送和肌营养不良症的治疗
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
US20220145274A1
(en)
|
2019-03-12 |
2022-05-12 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
US20220177863A1
(en)
|
2019-03-18 |
2022-06-09 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
MX2021011426A
(es)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Metodos y composiciones para editar secuencias de nucleótidos.
|
CN111718418B
(zh)
|
2019-03-19 |
2021-08-27 |
华东师范大学 |
一种增强基因编辑的融合蛋白及其应用
|
EP3942026A1
(de)
|
2019-03-22 |
2022-01-26 |
Université de Paris |
Neue inhibitoren der lrrk2/pp1-interaktion
|
EP3953461A4
(de)
|
2019-04-09 |
2023-05-31 |
The Regents of The University of California |
Langanhaltende analgesie durch gezielte epigenetische unterdrückung in vivo
|
AU2020270960A1
(en)
|
2019-04-12 |
2021-11-04 |
Ultragenyx Pharmaceutical Inc. |
Engineered producer cell lines and methods of making and using the same
|
WO2020210751A1
(en)
|
2019-04-12 |
2020-10-15 |
The Broad Institute, Inc. |
System for genome editing
|
CA3137080A1
(en)
|
2019-04-15 |
2020-10-22 |
Sanford Research |
Gene therapy for treating or preventing visual effects in batten disease
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
WO2020223274A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
EP3966227A1
(de)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
|
WO2020225606A1
(en)
|
2019-05-08 |
2020-11-12 |
Crispr Therapeutics Ag |
Crispr/cas all-in-two vector systems for treatment of dmd
|
EP3736330A1
(de)
|
2019-05-08 |
2020-11-11 |
European Molecular Biology Laboratory |
Partikel mit modifiziertem adeno-assoziiertem virus (aav) zur gentherapie
|
WO2020236352A1
(en)
|
2019-05-17 |
2020-11-26 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy targeting retinal cells
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
WO2020234363A2
(en)
|
2019-05-21 |
2020-11-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
|
KR20220011621A
(ko)
|
2019-05-23 |
2022-01-28 |
메조블라스트 인터내셔널 에스에이알엘 |
뇌경색의 기능적 회복
|
WO2020243485A1
(en)
|
2019-05-29 |
2020-12-03 |
Massachusetts Institute Of Technology |
Hiv-1 specific immunogen compositions and methods of use
|
EP3990636A1
(de)
|
2019-06-28 |
2022-05-04 |
CRISPR Therapeutics AG |
Materialien und verfahren zur steuerung der geneditierung
|
CA3145446A1
(en)
|
2019-07-02 |
2021-01-07 |
Fundacion Para La Investigacion Medica Aplicada |
Cpla2e inducing agents and uses thereof
|
CN112180094A
(zh)
|
2019-07-04 |
2021-01-05 |
上海东慈生物科技有限公司 |
Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
WO2021016075A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
KR20220035937A
(ko)
|
2019-07-25 |
2022-03-22 |
노파르티스 아게 |
조절 가능한 발현 시스템
|
EP4010474A1
(de)
|
2019-08-08 |
2022-06-15 |
The Broad Institute, Inc. |
Basiseditoren mit diversifiziertem zielbereich
|
EP4010465A1
(de)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
|
TW202120688A
(zh)
|
2019-08-12 |
2021-06-01 |
美商生命編輯公司 |
Rna導引之核酸酶及其活性片段及變體以及使用方法
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
WO2021032069A1
(en)
|
2019-08-16 |
2021-02-25 |
Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences |
Treatment of neuronal diseases
|
TW202120532A
(zh)
|
2019-08-21 |
2021-06-01 |
美國全美兒童醫院之研究學會 |
α肌聚糖之腺相關病毒載體遞送及肌肉萎縮症之治療
|
WO2021041485A1
(en)
|
2019-08-26 |
2021-03-04 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
EP4028514A1
(de)
|
2019-09-09 |
2022-07-20 |
Beam Therapeutics Inc. |
Neue crispr-enzyme, verfahren, systeme und verwendungen davon
|
WO2021050593A1
(en)
|
2019-09-09 |
2021-03-18 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of sod1
|
CN114729384A
(zh)
|
2019-09-12 |
2022-07-08 |
博德研究所 |
工程化腺相关病毒衣壳
|
WO2021072328A1
(en)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
CA3158131A1
(en)
|
2019-10-18 |
2021-04-22 |
Nicolas Sebastien Wein |
Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene
|
WO2021077115A1
(en)
|
2019-10-18 |
2021-04-22 |
Research Institute At Nationwide Children's Hospital |
Gene therapy targeting cochlear cells
|
EP4061943A1
(de)
|
2019-11-19 |
2022-09-28 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antisense-oligonukleotide und deren verwendung zur behandlung von krebs
|
IL293210A
(en)
|
2019-11-22 |
2022-07-01 |
Res Inst Nationwide Childrens Hospital |
Materials and methods for treating disorders associated with the ighmbp2 gene
|
WO2021108717A2
(en)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
EP4069845A1
(de)
|
2019-12-06 |
2022-10-12 |
Scribe Therapeutics Inc. |
Zusammensetzungen und verfahren für das targeting von rhodopsin
|
WO2021113769A1
(en)
|
2019-12-07 |
2021-06-10 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of htt
|
IL294072A
(en)
|
2019-12-20 |
2022-08-01 |
Res Inst Nationwide Childrens Hospital |
Gene therapy is efficient for targeting muscle in muscle diseases
|
AU2020417760A1
(en)
|
2019-12-30 |
2022-08-04 |
LifeEDIT Therapeutics, Inc. |
RNA-guided nucleases and active fragments and variants thereof and methods of use
|
JP2023510352A
(ja)
|
2020-01-10 |
2023-03-13 |
スクライブ・セラピューティクス・インコーポレイテッド |
Pcsk9の標的化のための組成物および方法
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
WO2021155065A1
(en)
|
2020-01-28 |
2021-08-05 |
The Broad Institute, Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
EP4100032A1
(de)
|
2020-02-05 |
2022-12-14 |
The Broad Institute Inc. |
Geneditierungsverfahren zur behandlung von spinaler muskelatrophie
|
WO2021158921A2
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
BR112022016391A2
(pt)
|
2020-02-18 |
2022-10-25 |
Res Inst Nationwide Childrens Hospital |
Alvejamento mediado por aav de mirna no tratamento de distúrbios ligados a x
|
WO2021173965A1
(en)
|
2020-02-28 |
2021-09-02 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
CN115461453A
(zh)
|
2020-03-16 |
2022-12-09 |
奥特吉尼克斯制药公司 |
提高重组腺相关病毒产率的方法
|
CA3172178A1
(en)
|
2020-03-18 |
2021-09-23 |
Benjamin OAKES |
Compositions and methods for the targeting of c9orf72
|
WO2021188960A1
(en)
|
2020-03-20 |
2021-09-23 |
University Of Florida Research Foundation, Inc. |
Gene therapy for cockayne syndrome
|
GB202004498D0
(en)
|
2020-03-27 |
2020-05-13 |
Ucl Business Ltd |
Activity-dependent gene therapy for neurological disorders
|
EP4163375A4
(de)
|
2020-03-30 |
2024-01-03 |
Wuhan Neurophth Biotechnology Ltd Company |
Expressionsvektor des menschlichen nuklearfaktor-e2-verwandten faktors 2 und anwendung des expressionsvektors
|
WO2021209521A1
(en)
|
2020-04-14 |
2021-10-21 |
Genethon |
Vectors for the treatment of acid ceramidase deficiency
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
AU2021260960A1
(en)
|
2020-04-22 |
2022-11-24 |
Dragonfly Therapeutics, Inc. |
Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
|
TW202208626A
(zh)
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna引導核酸酶及其活性片段與變體,以及使用方法
|
US20230159913A1
(en)
|
2020-04-28 |
2023-05-25 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
CN115715203A
(zh)
|
2020-05-06 |
2023-02-24 |
塞勒克提斯公司 |
对细胞进行基因修饰以递送治疗性蛋白质的方法
|
EP4146812A1
(de)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Verfahren zur gezielten einführung exogener sequenzen in zelluläre genome
|
IL297761A
(en)
|
2020-05-08 |
2022-12-01 |
Broad Inst Inc |
Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
|
CA3173882A1
(en)
|
2020-05-11 |
2021-11-18 |
Alexandra Briner CRAWLEY |
Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
|
JP2023528017A
(ja)
|
2020-05-26 |
2023-07-03 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
CA3185499A1
(en)
|
2020-06-09 |
2021-12-16 |
Genethon |
Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
|
WO2021250081A1
(en)
|
2020-06-09 |
2021-12-16 |
Genethon |
Nrf2 activator for use in treating dilated cardiomyopathies
|
CN116194474A
(zh)
|
2020-06-09 |
2023-05-30 |
吉尼松公司 |
遗传性扩张型心肌病的治疗
|
WO2021257595A1
(en)
|
2020-06-15 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
JP2023540429A
(ja)
|
2020-07-10 |
2023-09-25 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
てんかんを治療するための方法及び組成物
|
CN116157144A
(zh)
|
2020-07-15 |
2023-05-23 |
生命编辑制药股份有限公司 |
尿嘧啶稳定蛋白及其活性片段和变体以及使用方法
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
WO2022018638A1
(en)
|
2020-07-21 |
2022-01-27 |
Crispr Therapeutics Ag |
Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
|
KR20230093241A
(ko)
|
2020-07-27 |
2023-06-27 |
보이저 테라퓨틱스, 인크. |
글루코실세라미데이스 베타 결핍증과 관련된 신경 장애의 치료를 위한 조성물 및 방법
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
EP4192514A1
(de)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
|
JP2023536080A
(ja)
|
2020-08-06 |
2023-08-23 |
ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダ |
遺伝子治療によるアルツハイマー病などのタウオパチーの治療に使用するためのウイルス粒子
|
IL300263A
(en)
|
2020-08-07 |
2023-03-01 |
Spacecraft Seven Llc |
Plakophilin-2 (PKP2) gene therapy using an AAV vector
|
US20230265456A1
(en)
|
2020-08-10 |
2023-08-24 |
Fundacion Para La Investigacion Medica Aplicada |
Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
|
US20230304047A1
(en)
|
2020-08-11 |
2023-09-28 |
University Of Oslo |
Improved gene editing
|
EP4204545A2
(de)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T-zellen mit verbesserter funktionalität
|
TW202227634A
(zh)
|
2020-09-08 |
2022-07-16 |
美商薩羅塔治療公司 |
表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
|
MX2023002848A
(es)
|
2020-09-11 |
2023-03-22 |
Lifeedit Therapeutics Inc |
Enzimas modificadoras del acido desoxirribonucleico (adn) y fragmentos activos y sus variantes y metodos de uso.
|
US20230357795A1
(en)
|
2020-09-15 |
2023-11-09 |
Research Institute At Nationwide Children's Hospital |
Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
|
AU2021349277A1
(en)
|
2020-09-28 |
2023-05-11 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treating muscular dystrophy
|
CA3200563A1
(en)
|
2020-09-29 |
2022-04-07 |
Genethon |
Enhancing utrophin expression in cell by inducing mutations within utrophin regulatory elements and therapeutic use thereof
|
US20230392134A1
(en)
|
2020-09-30 |
2023-12-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
JP2023544264A
(ja)
|
2020-10-09 |
2023-10-23 |
ユーシービー バイオファルマ エスアールエル |
核酸構築物、ウイルスベクター及びウイルス粒子
|
EP4229204A1
(de)
|
2020-10-15 |
2023-08-23 |
F. Hoffmann-La Roche AG |
Nukleinsäurekonstrukte zur gleichzeitigen genaktivierung
|
MX2023004052A
(es)
|
2020-10-15 |
2023-05-03 |
Hoffmann La Roche |
Constructos de acido nucleico para transcripcion de arn asociado a un virus (arn va).
|
IL302128A
(en)
|
2020-11-02 |
2023-06-01 |
Biomarin Pharm Inc |
A process for the enrichment of adeno-associated virus
|
TW202233584A
(zh)
|
2020-11-11 |
2022-09-01 |
歐洲分子生物學實驗室 |
用於基因治療之經修飾病毒顆粒
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
AU2021385595A1
(en)
|
2020-11-30 |
2023-06-29 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
|
US20240100185A1
(en)
|
2020-12-03 |
2024-03-28 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of ptbp1
|
AU2021400745A1
(en)
|
2020-12-17 |
2023-07-20 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
|
US20240091382A1
(en)
|
2020-12-23 |
2024-03-21 |
Vivet Therapeutics |
Minimal bile acid inducible promoters for gene therapy
|
CA3209471A1
(en)
|
2021-01-27 |
2022-08-04 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
|
CA3210662A1
(en)
|
2021-02-03 |
2022-08-11 |
Research Institute At Nationwide Children's Hospital |
Compositions and methods for treating disease associated with dux4 overexpression
|
WO2022170038A1
(en)
|
2021-02-05 |
2022-08-11 |
Amicus Therapeutics, Inc. |
Adeno-associated virus delivery of cln3 polynucleotide
|
AU2022229489A1
(en)
|
2021-03-04 |
2023-08-31 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications
|
CN115427561A
(zh)
|
2021-03-09 |
2022-12-02 |
辉大(上海)生物科技有限公司 |
工程化CRISPR/Cas13系统及其用途
|
AR125191A1
(es)
|
2021-03-22 |
2023-06-21 |
Lifeedit Therapeutics Inc |
Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso
|
CN117529555A
(zh)
|
2021-03-23 |
2024-02-06 |
比姆医疗股份有限公司 |
新颖crispr酶、方法、系统及其用途
|
WO2022221424A1
(en)
|
2021-04-13 |
2022-10-20 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery
|
CA3215435A1
(en)
|
2021-04-16 |
2022-10-20 |
Giuseppe Ciaramella |
Genetic modification of hepatocytes
|
EP4326752A1
(de)
|
2021-04-23 |
2024-02-28 |
Research Institute at Nationwide Children's Hospital |
Produkte und verfahren zur behandlung von muskeldystrophie
|
EP4334447A1
(de)
|
2021-05-07 |
2024-03-13 |
UCL Business Ltd |
Abca4-genomeditierung
|
AU2022279062A1
(en)
|
2021-05-17 |
2024-01-04 |
Sarepta Therapeutics, Inc. |
Production of recombinant aav vectors for treating muscular dystrophy
|
AU2022277649A1
(en)
|
2021-05-21 |
2023-11-30 |
Cellectis S.A. |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
WO2022247873A1
(zh)
|
2021-05-27 |
2022-12-01 |
中国科学院动物研究所 |
工程化的Cas12i核酸酶、效应蛋白及其用途
|
EP4108263A3
(de)
|
2021-06-02 |
2023-03-22 |
Research Institute at Nationwide Children's Hospital |
Rekombinante adeno-assoziierte virusprodukte und verfahren zur behandlung von gliedergürtel-muskeldystrophie 2a
|
WO2022258755A1
(en)
|
2021-06-09 |
2022-12-15 |
Universität Duisburg-Essen |
Method for immortalising vesicle-secreting cells
|
WO2022261509A1
(en)
|
2021-06-11 |
2022-12-15 |
The Broad Institute, Inc. |
Improved cytosine to guanine base editors
|
WO2022261394A1
(en)
|
2021-06-11 |
2022-12-15 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
IL308896A
(en)
|
2021-06-11 |
2024-01-01 |
Bayer Ag |
Programmable type V RNA endoclase systems
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
WO2023004367A2
(en)
|
2021-07-20 |
2023-01-26 |
The Broad Institute, Inc. |
Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
|
WO2023012165A1
(en)
|
2021-08-02 |
2023-02-09 |
Universite De Montpellier |
Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
|
WO2023017098A2
(en)
|
2021-08-11 |
2023-02-16 |
King's College London |
Compositions and methods for improved treatment of disorders affecting the central nervous system
|
AU2022328215A1
(en)
|
2021-08-11 |
2024-03-07 |
Solid Biosciences Inc. |
Treatment of muscular dystrophy
|
WO2023023220A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
|
WO2023023227A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
|
WO2023034980A1
(en)
|
2021-09-03 |
2023-03-09 |
Bomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034990A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034994A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034996A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034997A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
WO2023034989A1
(en)
|
2021-09-03 |
2023-03-09 |
Biomarin Pharmaceutical Inc. |
Aav capsid compositions and methods for delivery
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
WO2023042104A1
(en)
|
2021-09-16 |
2023-03-23 |
Novartis Ag |
Novel transcription factors
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
CA3234702A1
(en)
|
2021-10-07 |
2023-04-13 |
Research Institute At Nationwide Children's Hospital |
Products and methods for myelin protein zero silencing and treating cmt1b disease
|
WO2023060233A1
(en)
|
2021-10-08 |
2023-04-13 |
Amicus Therapeutics, Inc. |
Biomarkers for lysosomal storage diseases
|
EP4219726A1
(de)
|
2021-10-15 |
2023-08-02 |
Research Institute at Nationwide Children's Hospital |
Selbstkomplementärer adeno-assoziierter virusvektor und dessen verwendung bei der behandlung von muskeldystrophie
|
WO2023070072A1
(en)
|
2021-10-21 |
2023-04-27 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Retroelement-generated transcription factor decoys
|
WO2023073071A1
(en)
|
2021-10-28 |
2023-05-04 |
UCB Biopharma SRL |
Nucleic acid constructs, viral vectors and viral particles
|
WO2023077078A1
(en)
|
2021-10-29 |
2023-05-04 |
Ultragenyx Pharmaceutical Inc. |
Engineered cell lines for increased production of recombinant adeno-associated virus (raav)
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
CN114015674A
(zh)
|
2021-11-02 |
2022-02-08 |
辉二(上海)生物科技有限公司 |
新型CRISPR-Cas12i系统
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023091949A2
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
US20230279431A1
(en)
|
2021-11-30 |
2023-09-07 |
Research Institute At Nationwide Children's Hospital |
Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy
|
EP4198047A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Erhöhung des gentransfers von fukutin-verwandtem protein unter verwendung modifizierter itr-sequenzen
|
EP4198134A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Transfererhöhung des gamma-sarcoglycan-gens unter verwendung von modifizierten itr-sequenzen
|
EP4198048A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Calpain-3-gentransfersteigerung unter verwendung von modifizierten itr-sequenzen
|
EP4198046A1
(de)
|
2021-12-16 |
2023-06-21 |
Genethon |
Erhöhung des gentransfers von alpha-sarcoglykan unter verwendung von modifizierten itr-sequenzen
|
WO2023114953A2
(en)
|
2021-12-17 |
2023-06-22 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
WO2023122669A1
(en)
|
2021-12-21 |
2023-06-29 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of limb girdle muscular dystrophy
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023131682A1
(en)
|
2022-01-06 |
2023-07-13 |
Ucl Business Ltd |
Endogenous gene regulation to treat neurological disorders and diseases
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023139557A1
(en)
|
2022-01-24 |
2023-07-27 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2023147511A2
(en)
*
|
2022-01-28 |
2023-08-03 |
Shape Therapeutics Inc. |
Systems for amplification of aav rep and cap proteins
|
GB202201744D0
(en)
|
2022-02-10 |
2022-03-30 |
Ucl Business Ltd |
Treatment of acquired focal epilepsy
|
WO2023168400A2
(en)
|
2022-03-03 |
2023-09-07 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
|
WO2023183589A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Rt-dna fidelity and retron genome editing
|
WO2023183627A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
|
WO2023183588A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods of assessing engineered retron activity, and uses thereof
|
WO2023196802A1
(en)
|
2022-04-04 |
2023-10-12 |
The Broad Institute, Inc. |
Cas9 variants having non-canonical pam specificities and uses thereof
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023196772A1
(en)
|
2022-04-04 |
2023-10-12 |
Beam Therapeutics Inc. |
Novel rna base editing compositions, systems, methods and uses thereof
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023220693A1
(en)
|
2022-05-12 |
2023-11-16 |
SunVax mRNA Therapeutics Inc. |
Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
|
WO2023222829A1
(en)
|
2022-05-17 |
2023-11-23 |
Centre Hospitalier Universitaire Vaudois |
Designed biosensors for enhanced t cell therapy
|
WO2023225564A1
(en)
|
2022-05-18 |
2023-11-23 |
The Broad Institute, Inc. |
Engineered viral capsids with increased stability and methods of use thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023227438A1
(en)
|
2022-05-23 |
2023-11-30 |
F. Hoffmann-La Roche Ag |
Raman-based method for the differentiation of aav particle serotype and aav particle loading status
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
WO2023232922A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2023240157A2
(en)
|
2022-06-08 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of dmd
|
WO2023240177A1
(en)
|
2022-06-08 |
2023-12-14 |
Research Instiitute At Nationwide Children's Hospital |
Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
|
WO2023240137A1
(en)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024011115A1
(en)
|
2022-07-06 |
2024-01-11 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery of cln1 polynucleotide
|
WO2024016003A2
(en)
|
2022-07-14 |
2024-01-18 |
The Broad Institute, Inc. |
Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
|
WO2024013239A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024035782A1
(en)
|
2022-08-10 |
2024-02-15 |
Aav Gene Therapeutics, Inc. |
Aav-mediated intramuscular delivery of insulin
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024038168A1
(en)
|
2022-08-19 |
2024-02-22 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such
|
WO2024044673A1
(en)
|
2022-08-24 |
2024-02-29 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Dual cut retron editors for genomic insertions and deletions
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024042489A1
(en)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
WO2024042168A1
(en)
|
2022-08-26 |
2024-02-29 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
|
WO2024042165A2
(en)
|
2022-08-26 |
2024-02-29 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
|
WO2024056561A1
(en)
|
2022-09-12 |
2024-03-21 |
F. Hoffmann-La Roche Ag |
Method for separating full and empty aav particles
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024059791A1
(en)
|
2022-09-16 |
2024-03-21 |
Beam Therapeutics Inc. |
Large serine recombinases, systems and uses thereof
|
WO2024056902A2
(en)
|
2022-09-16 |
2024-03-21 |
Christopher Shaw |
Compositions and methods for treating neurological diseases
|
WO2024064913A1
(en)
|
2022-09-23 |
2024-03-28 |
Sarepta Therapeutics, Inc. |
Recombinant aav vectors for treating muscular dystrophy
|
WO2024081706A1
(en)
|
2022-10-11 |
2024-04-18 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
|